Stocktwits on MSN18h
Sarepta Therapeutics Temporarily Halts Three Clinical Studies Of Elevidys: Retail Is Dull While Stock Drops
Shares of Sarepta Therapeutics, Inc. (SRPT) traded over 2% lower in afternoon trade on Friday after the company said it has ...
The American Journal of Managed Care21h
Key Considerations for Choosing the Right SMA Treatment
FDA-approved treatments for spinal muscular atrophy differ in their mechanisms of action, safety profiles, and administration ...
Muscular Dystrophy News23hOpinion
Respecting autonomy in Duchenne treatment
Shalom Lim, who has Duchenne muscular dystrophy, shares how caregivers can support patient autonomy when it comes to ...
Muscular Dystrophy News23h
Finding motivation in Duchenne regimen effort
Hawkin Miller, who has Duchenne muscular dystrophy, shares motivation and advice for staying on track with treatment.
Sarepta Therapeutics Provides Update on ELEVIDYS
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, shared the following ...